Drug intelligence / Profile preview

atbody

Development stage: Preclinical
Lead developer: ATB Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Atbody is a novel therapeutic antibody format developed by ATB Therapeutics designed to treat cancer and autoimmune diseases. It consists of a single entity composed of an antibody that delivers a potent peptide payload, which is released inside the target cancer cell following cleavage of a peptide linker. This unique composition and mechanism provide increased potency, stability, and superior targeted exposure compared to traditional antibody-drug conjugates. The design aims to improve the therapeutic window by reducing the dose needed without compromising efficacy.

Beyond the preview

Go deeper on atbody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atbody.

Explore the full profile